Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued
Reference number: GID-TA10244
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for gastric or gastroesophageal junction adenocarcinoma.
For information, the company have advised that they no longer intend to make a submission for this indication at this time because the technology will not be launched in the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.